Connect with us

Health

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Reveals 2018 Clinical And Corporate Update

Published

on

Zynerba Pharmaceuticals (NASDAQ:ZYNE) announced that it will focus on rare and near-rare neurological and psychiatric disorders that have the highest unmet medical needs. The company also intends to expand its ZYN002 in Phase 2/3 program that outlines the Fragile X syndrome (FXS) and Phase 2 programs to assess the refractory epilepsies conditions including the adult refractory focal epilepsy and other developmental and epileptic encephalopathies (DEE) found in pediatric and adolescent patients.

In addition, the company plans to launch Phase 2 development of ZYN001 in Tourette syndrome by end of the year. The resolution to focus on the rare and near-rare neurological and psychiatric disorders is basically due to a variety of essential factors such as the forceful ZYN002 clinical data seen in the Fragile X syndrome and the refractory focal epilepsy, according to Armando Anido, Chairman and CEO of Zynerba.

Concentrating on both rare and near-rare strategy also allows the company to maximize on both ZYN001 and ZYN002 with the possibility of improving the product pricing across all indications. Anido believes that Zynerba is well positioned to execute on its new strategy, since it has sufficient capital to fund all the required operations up to 2019.

Zynerba is looking forward to deliver several corporate and clinical achievements that could be significant to its stakeholders including the investors and patients. According to Anido, 2018 seems to be a year of great evolution for the company. The firm also intends to gather significant data from the ongoing open-label extension studies in both the Fragile X syndrome and adult refractory focal epilepsy that would be published by end of the year.

Zynerba is one of the pharmaceutical companies that operate with a zero-debt on its balance sheet. Hence the company has the capability to maximize on its capital returns by increasing its debt since it has low cost of capital. However, the company must adhere to the strict debt obligations that could potentially reduce its financial flexibility.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of MMJReporter.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Title

Uncategorized23 hours ago

Best Oil Producers of 2018

Millionaires are being made by the moment in the medical marijuana industry. Venture capital firms, private equity firms, and even...

MyDx Inc MyDx Inc
Health2 weeks ago

MyDx Inc. (OTCMKTS:MYDX) Initiates Clinical Trial of Cannabis Formula for The Treatment of Chronic Low Back Pain

San Diego, CA based MyDx Inc. (OTCMKTS:MYDX) has announced the controlled trial of the cannabis formula for the treatment of...

Business2 weeks ago

Fastfunds Financial Corporation (OTCMKTS:FFFC) Is All Set to Launch Affinity Connextions Program Targeting MMJ Industry

Fastfunds Financial Corporation (OTCMKTS:FFFC) has announced the completion of all necessary formalities to introduce an Affinity Connextions Program through a...

Innovative Industrial Properties Inc Innovative Industrial Properties Inc
Business2 weeks ago

Innovative Industrial Properties, Inc (NYSE:IIPR) Unveils Exercise Of Underwriter’s Option To Purchase Common Stock Shares

Innovative Industrial Properties, Inc (NYSE:IIPR) announced recently that it has obtained the exercise of the underwriter’s option to buy additional...

Business2 weeks ago

Next Generation Management Corporation (OTCMKTS:NGMC) Updates On New Medical Marijuana System in Oregon

Nextgen Holdings, a subsidiary of the Next Generation Management Corporation (OTCMKTS:NGMC) recently updated its stockholders with the ongoing Medical Marijuana...

INDUSTRIAL HEMP2 weeks ago

Weed Inc’s (OTCMKTS:BUDZ) Performance Is Getting Higher

Weed Inc (OTCMKTS:BUDZ) has for a long time been enjoying the momentous highs for the past few months. The company’s...

INDUSTRIAL HEMP2 weeks ago

Namaste Technologies Inc (OTCMKTS:NXTTF) Signs A Share Purchase Agreement With Cannbit Ltd

Namaste Technologies Inc (OTCMKTS:NXTTF) announced recently that it signed a non-binding Letter of Intent (LOI) with Cannabit Limited where the...

INDUSTRIAL HEMP2 weeks ago

MariMed Inc. (OTCMKTS:MRMD) Plans To Expand Its Cannabis Business

MeriMed Inc. (OTCMKTS:MRMD) announced its grand plans to expand business into the emerging cannabis industry. Furthermore, the company intends to...

INDUSTRIAL HEMP2 weeks ago

Kush Bottles Inc (OTCMKTS:KSHB)’ Q1 Results For Fiscal Year 2018 Released

Leading supplier and service provider to the cannabis sector, Kush Bottles Inc (OTCMKTS:KSHB), has released financial results for 2018’s first...

INDUSTRIAL HEMP2 weeks ago

Wanderport Corp. (OTCMKTS:WDRP) Will Accept The Use Of Bitcoin In Its E-Commerce Store

Wanderport Corp. (OTCMKTS:WDRP) has made good its promise of allowing full access to the Company’s full suite of products. The...

Advertisement
Advertisement